|
1
|
Yang M and Yu X: Management of bone
metastasis with intravenous bisphosphonates in breast cancer: A
systematic review and meta-analysis of dosing frequency. Support
Care Cancer. 28:2533–2540. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jeon HL, Oh IS, Baek YH, Yang H, Park J,
Hong S and Shin JY: Zoledronic acid and skeletal-related events in
patients with bone metastatic cancer or multiple myeloma. J Bone
Miner Metab. 38:254–263. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Van Poznak C, Somerfield MR, Barlow WE,
Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS,
Eisen A, Frank ES, et al: Role of bone-modifying agents in
metastatic breast cancer: An American Society of Clinical
Oncology-cancer care Ontario focused guideline update. J Clin
Oncol. 35:3978–3986. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cardoso F, Senkus E, Costa A, Papadopoulos
E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh
J, et al: 4th ESO-ESMO International Consensus Guidelines for
Advanced Breast Cancer (ABC 4). Ann Oncol. 29:1634–1657.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Migliorati CA, Siegel MA and Elting LS:
Bisphosphonate-associated osteonecrosis: A long-term complication
of bisphosphonate treatment. Lancet Oncol. 7:508–514.
2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mont MA, Zywiel MG, Marker DR, McGrath MS
and Delanois RE: The natural history of untreated asymptomatic
osteonecrosis of the femoral head: A systematic literature review.
J Bone Joint Surg Am Volume. 92:2165–2170. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gangji V, Soyfoo MS, Heuschling A, Afzali
V, Moreno-Reyes R, Rasschaert J, Gillet C, Fils JF and Hauzeur JP:
Non traumatic osteonecrosis of the femoral head is associated with
low bone mass. Bone. 107:88–92. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takahashi M, Ozaki Y, Kizawa R, Masuda J,
Sakamaki K, Kinowaki K, Umezu T, Kondoh C, Tanabe Y, Tamura N, et
al: Atypical femoral fracture in patients with bone metastasis
receiving denosumab therapy: A retrospective study and systematic
review. BMC Cancer. 19(980)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lee YK, Ha YC, Cho YJ, Suh KT, Kim SY, Won
YY, Min BW, Yoon TR, Kim HJ and Koo KH: Does zoledronate prevent
femoral head collapse from osteonecrosis? A prospective,
randomized, open-label, multicenter study. J Bone Joint Surg Am.
97:1142–1148. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Russell RG, Watts NB, Ebetino FH and
Rogers MJ: Mechanisms of action of bisphosphonates: Similarities
and differences and their potential influence on clinical efficacy.
Osteoporos Int. 19:733–759. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ristow O, Gerngross C, Schwaiger M,
Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Otto S and Pautke
C: Is bone turnover of jawbone and its possible over suppression by
bisphosphonates of etiologic importance in pathogenesis of
bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg.
72:903–910. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Weinstein RS: Glucocorticoid-induced
osteonecrosis. Endocrine. 41:183–190. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mont MA, Pivec R, Banerjee S, Issa K,
Elmallah RK and Jones LC: High-dose corticosteroid use and risk of
hip osteonecrosis: Meta-analysis and systematic literature review.
J Arthroplast. 30:1506–1512.e5. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dharmshaktu P, Aggarwal A, Dutta D and
Kulshreshtha B: Bilateral femoral head avascular necrosis with a
very low dose of oral corticosteroid used for panhypopituitarism.
BMJ Case Rep. 2016:2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bal O, Oksuzoglu B, Dogan M, Durnali A,
Uyeturk U, Demirci A, Arslan UY, Ekinci AS, Yildirim N, Alkis N and
Kilic S: Long-term outcomes of prolonged bisphosphonates more than
2 years in bone metastatic breast cancer: Risk vs benefit. Ir J Med
Sci. 189:805–810. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rossi L, Lascio SD, Kouros M and Pagani O:
A rare avascular osteonecrosis of the knee related to
bisphosphonate treatment in a patient with metastatic breast
cancer. Breast Dis. 35:203–206. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lyles KW, Colón-Emeric CS, Magaziner JS,
Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C,
Nordsletten L, Moore KA, et al: Zoledronic acid and clinical
fractures and mortality after hip fracture. N Engl J Med.
357:1799–1809. 2007.PubMed/NCBI View Article : Google Scholar
|
